Nuclear Medicine & Radiation Therapy

Andrew Scott Kennedy

Andrew Scott Kennedy
Physician in Chief, Radiation Oncology, Sarah Cannon Research Institute
USA

Biography

Mr. Andrew Scott Kennedy, MD, FACRO has been Physician-in-Chief of Radiation Oncology and Director of Radiation Oncology Research at Sarah Cannon Research Institute, LLC since joining in 2012. Mr. Kennedy is responsible for strategic development of radiation oncology services for the HCA Enterprise and development of radiation oncology research program within Sarah Cannon Research Institute. He has been Co-Medical Director of Sirtex Medical Inc. since January 22, 2010. Mr. Kennedy served as Co-Medical Director of Wake Radiology Oncology Services, P.L.L.C. in Cary, North Carolina since 2002. He served as Chief Medical and Science Officer of Oncologix Tech, Inc. a subsidiary of BestNet Communications Corporation until December 2007. He has primary activity in providing patients with treatments for cancer, specializing in gastrointestinal cancers, as well as cancers of the breast, lung and cervix. He served as Associate Professor in the Radiation Oncology and Head of GI radiation oncology at The University of Maryland School of Medicine and Residency program Director. He is an internationally known radiation oncologist and has given numerous presentations on radiation therapy for the treatment of colorectal and liver cancer and was instrumental in reintroducing an important new treatment for liver cancer, called infusion of microspheres, which offers hope to patients who have not had success with chemotherapy. Mr. Kennedy developed the most commonly used protocol in the US for infusion of microspheres and also has written many peer-reviewed scientific papers, articles, book chapters and abstracts on radiation oncology and has been invited to give presentations on radiation therapy for GI cancers and infusion of microspheres at the premier medical conferences in the United States, Asia and Europe. He served as Director of Oncologix Corporation, a subsidiary of BestNet Communications Corporation. He served as Director of Oncologix Tech, Inc., a subsidiary of BestNet Communications Corp. since July 26, 2006. He has been selected yearly since 2009 as one of America's Best Doctors (top 5 percent of U.S.), and was inducted into Alpha Omega Alpha (AOA) Honor Society as a faculty member in 1999. Mr. Kennedy is a graduate of Loma Linda School of Medicine, in Loma Linda, California and completed his residency at The University of North Carolina at Chapel Hill, where, as chief resident and later a research fellow, he completed significant work in three-dimensional treatment planning (3D external beam radiation therapy) and radiobiology research.

Research Interest

His research interest includes Pharmacology, Chemical Biology, Pathology.